Larry Goldenberg

Zenith Epigenetics Announces a Publication Highlighting the Role of ZEN-3694 in Overcoming Resistance to Therapies in Metastatic Castration-Resistant Prostate Cancer

Retrieved on: 
Thursday, June 24, 2021
Cancer, Anatomy, Branches of biology, Prostate cancer, Histopathology, Prostate, Active surveillance of prostate cancer, Larry Goldenberg

The study , led by a team of renowned prostate cancer researchers, has been published in Clinical Cancer Research, a high impact journal.

Key Points: 
  • The study , led by a team of renowned prostate cancer researchers, has been published in Clinical Cancer Research, a high impact journal.
  • This treatment induced neuroendocrine prostate cancer is becoming more prevalent with increasing use of ARSis and is associated with very poor patient clinical outcomes.
  • Prostate cancer is the second most commonly diagnosed cancer among men and the fifth most common cause of male cancer death worldwide.
  • Zenith Epigenetics is developing various novel combinations of BET inhibitors with other targeted agents.

Urology Care Foundation and American Urological Association send condolences to family, friends of Thomas V. Mike Miller, media reports indicate longtime president of Maryland Senate died of prostate cancer

Retrieved on: 
Saturday, January 16, 2021
Medical specialties, Clinical medicine, Medicine, Prostate cancer, Urology, Prostate, Cancer screening, National Prostate Health Month, Larry Goldenberg

Prostate cancer is the second most common cancer in men, with a new case diagnosed every 2.1 minutes.

Key Points: 
  • Prostate cancer is the second most common cancer in men, with a new case diagnosed every 2.1 minutes.
  • "Prostate cancer is the second most common cancer in men, with a new case being diagnosed every 2.1 minutes," said Harris M. Nagler, MD, President of the Urology Care Foundation.
  • Talk to your Doctor about prostate cancer screening if you are age 40 to 54 years and:
    There are many treatment options for prostate cancer.
  • About the Urology Care Foundation:The Urology Care Foundation is the world's leading nonprofit urological health foundation, and the official foundation of the American Urological Association.

Sophiris Bio Receives Positive Feedback from FDA Regarding Phase 3 Localized Prostate Cancer Clinical Trial Design

Retrieved on: 
Monday, October 21, 2019
Health, Prostate cancer, Histopathology, RTT, Food and Drug Administration, Larry Goldenberg, Prostate Cancer Foundation

The Phase 3 study design agreed upon with the FDA is consistent with the design previously agreed upon with the European Medicines Agency, as reported in June of this year.

Key Points: 
  • The Phase 3 study design agreed upon with the FDA is consistent with the design previously agreed upon with the European Medicines Agency, as reported in June of this year.
  • "The meeting with the FDA was positive, confirming the proposed Phase 3 study design is an acceptable approach to targeted focal therapy in the proposed patient population.
  • Prostate cancer is the second most common form of cancer in men in the United States with an estimated 175,000 new cases in 2019.
  • Sophiris Bio Inc. is a late-stage clinical biopharmaceutical company developing topsalysin (PRX302) for the treatment of patients with urological diseases.